Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
On this page:OverviewPublicationsResearchersKey papersJournalsOpen accessInstitutions
ScholarIQanswers from OpenAlex

Neuroendocrine Tumor Research Advances

TopicLeading institutions, researchers & key papers

This cluster of papers focuses on the epidemiology, classification, management, and treatment of neuroendocrine tumors, with a specific emphasis on pancreatic neuroendocrine tumors. It covers topics such as somatostatin receptor-based imaging and therapy, MEN1 syndrome, peptide receptor radionuclide therapy, genetic mutations associated with these tumors, and survival analysis.

550
Works

How has Neuroendocrine Tumor Research Advances's publication output changed over time?

ScholarIQpublication output · 2006–2020

Output grew0% over the shown period — from 1 works in 2006 to 1 in 2020.

1
2
1
3
1
1
1
2
2
1
2006200820092011201220142015201620172020

What are the most-cited papers on Neuroendocrine Tumor Research Advances?

ScholarIQmost cited works
One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States
James C. Yao, Manal M. Hassan, Alexandria T. Phan, Cecile G. Dagohoy, Colleen Leary, Jeannette E. Mares, Eddie K. Abdalla, Jason B. Fleming, Jean‐Nicolas Vauthey, Asif Rashid, Douglas B. Evans
Journal of Clinical Oncology. 20084,541 Citations
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
Arvind Dasari, Chan Shen, Daniel M. Halperin, Bo Zhao, Shouhao Zhou, Ying Xu, Ya‐Chen Tina Shih, James C. Yao
JAMA Oncology. 20173,498 CitationsOPEN ACCESS
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin, Andrew Hendifar, James C. Yao, Beth Chasen, Erik Mittra, Pamela L. Kunz, Matthew H. Kulke, Heather A. Jacene, David Bushnell, Thomas M. O’Dorisio, Richard P. Baum, Harshad Kulkarni, Martyn Caplin, Rachida Lebtahi, Timothy J. Hobday, Ebrahim S. Delpassand, Eric Van Cutsem, Al B. Benson, Rajaventhan Srirajaskanthan, Marianne Pavel, Jaime Font de Mora, Jordan Berlin, Enrique Grande, Nicholas S. Reed, Ettore Seregni, Kjell Öberg, Maribel Lopera Sierra, Paola Santoro, Thomas Thevenet, Jack L. Erion, Philippe Ruszniewski, Dik J. Kwekkeboom, Eric P. Krenning
New England Journal of Medicine. 20173,241 CitationsOPEN ACCESS
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
James C. Yao, Manisha H. Shah, Tetsuhide Ito, C. Lombard Bohas, Edward M. Wolin, Eric Van Cutsem, Timothy J. Hobday, Takuji Okusaka, Jaume Capdevila, Elisabeth G.E. de Vries, Paola Tomassetti, Marianne Pavel, Sakina Hoosen, T Haas, Jeremie Lincy, David Lebwohl, Kjell Öberg
New England Journal of Medicine. 20112,863 CitationsOPEN ACCESS
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Éric Raymond, Laëtitia Dahan, Jean‐Luc Raoul, Yung‐Jue Bang, Ivan Borbath, Catherine Lombard‐Bohas, Juan W. Valle, Peter Metrakos, Denis Smith, Aaron I. Vinik, Jen‐Shi Chen, Dieter Hörsch, Pascal Hammel, Bertram Wiedenmann, Eric Van Cutsem, Shem Patyna, Dongrui R. Lu, C. Blanckmeister, Richard C. Chao, Philippe Ruszniewski
New England Journal of Medicine. 20112,553 Citations

Where is Neuroendocrine Tumor Research Advances research published, and who funds it?

ScholarIQvenues & funding sources

TOP FUNDERS

National Science Foundation
NIH
Wellcome Trust
European Research Council
Funder breakdown is a member featureSign up free to unlock

How much of the research on Neuroendocrine Tumor Research Advances is open access?

ScholarIQopen access share
53%OPEN ACCESS
Gold
0%
Green
7%
Hybrid
13%
Bronze
33%
Closed
47%

Related on ScholarIQ

One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States
Paper
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Paper
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
Paper
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
Paper
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
Paper
Consensus statement on the pathology of IgG4-related disease
Paper
470M+ articles · free account